Motor, Non-motor and Genetic Determinants of Progression in Parkinson's Disease: A Mexican Multicenter Cohort Study (ReMePARK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01865877|
Recruitment Status : Completed
First Posted : May 31, 2013
Last Update Posted : March 3, 2017
The objective of the study is to assess the effect of motor, non-motor and genetic factors on the progression of Parkinson's disease as well as its impact on complications rates.
A large sample of Mexican subjects with Parkinson's disease attending several referral centers will be included.
Data collected will include disease severity and motor scales, non-motor scales as well as genotyping for monogenic forms of the disease.
Assessments will be performed every 6 months for two years.
|Condition or disease|
Demographic and clinical data will be collected after obtaining a signed informed consent.
Recruitment will be competitive. Data collected includes age, gender, motor phenotype, age at onset, age at diagnosis, smoking history, family history, antiparkinsonic treatment, other treatments and a complete neurological evaluation.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||550 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Motor, Non-motor and Genetic Determinants of Progression and Complications in Parkinson's Disease: A Multicenter Cohort Study in Mexican Population (ReMePArk)|
|Study Start Date :||August 2012|
|Actual Primary Completion Date :||August 2016|
|Actual Study Completion Date :||August 2016|
Subjects diagnosed with Parkinson's disease
- To assess motor scale change over time [ Time Frame: Every 6 months for 2 years ]Motor symptoms will be assessed by proper and validated motor scales; also minimal clinically important change will be determined.
- To assess non-motor symptoms over time [ Time Frame: Every 6 months for 2 years ]Non-motor symptoms will be assessed using proper validated scales. Frequency and severity will be recorded.
- To assess quality of life change over time. [ Time Frame: Every 6 months for 2 years ]Health-related quality of life will be assessed with proper validated clinimetric instruments.
- To assess caregiver burden as disease progresses [ Time Frame: Every 12 months for 2 years ]Caregiver burden will be assessed by proper validated scales.
- To assess the change in prevalence of neuropsychiatric symptoms over time [ Time Frame: Every 12 months for 2 years ]Prevalence and incidence of depression, apathy, cognitive decline, psychosis and impulse control disorder will be determined.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01865877
|Hospital Civil de Guadalajara|
|Guadalajara, Jalisco, Mexico, 44280|
|Monterrey, Nuevo León, Mexico, 64460|
|Hospital Regional #1|
|Mérida, Yucatán, Mexico, 97134|
|Hospital General de México|
|Mexico City, Mexico, 06726|
|Instituto Nacional de Neurología y Neurocirugía|
|Mexico City, Mexico, 14269|
|San Luis Potosí, Mexico, 23000|
|Hospital General de Zacatecas|
|Zacatecas, Mexico, 11340|
|Principal Investigator:||Amin Cervantes-Arriaga, MD,MSc||Instituto Nacional de Neurología y Neurocirugía|